2017 |
R21 |
CA231000-01A1 |
KENNEDY, DANIEL ROBERT (contact); ZWICKER, JEFFREY |
Response to PQ12 - Using thiol isomerase inhibitors to diminish cancer induced thrombosis |
2017 |
R01 |
CA231267-01 |
FEHRENBACHER, JILL C (contact); KELLEY, MARK R |
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN) |
2017 |
R01 |
CA227493-01 |
MARPLES, BRIAN (contact); FORNONI, ALESSIA |
(PQ 12) Targeting SMPDL3b to Prevent Radiation-Induced Nephrotoxicity |
2017 |
R01 |
CA219637-01A1 |
DAMAJ, M IMAD (contact); GEWIRTZ, DAVID A |
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy |
2017 |
R01 |
CA219829-01A1 |
ZHANG, ZHENG GANG |
Exosomes and platinum-induced peripheral neuropathy |
2019 |
R01 |
CA242158-01 |
JANG, MI-HYEON |
PQ#12; Targeting Nampt-mediated NAD+ metabolism in chemobrain |
2019 |
R01 |
CA227517-01A1 |
TANIGUCHI, CULLEN MITSUO |
Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer |
2017 |
R01 |
CA220002-01A1 |
BURRIDGE, PAUL W (contact); STRANGER, BARBARA E |
Genomic Prediction of Doxorubicin-Induced Cardiotoxicity |
2019 |
R21 |
CA231131-01A1 |
CARSON, JAMES A |
(PQ 12) The Regulation of Physical Function and Skeletal Muscle Metabolic Signaling After Cessation of 5-Fluorouracil Treatment |
2017 |
R01 |
CA227064-01 |
KAVELAARS, ANNEMIEKE (contact); HEIJNEN, COBI J |
PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain |
2019 |
R01 |
CA238946-01 |
LUSTBERG, MARYAM B (contact); HU, SHUIYING |
Prevention of paclitaxel-induced peripheral neuropathy with nilotinib |
2017 |
R01 |
CA231219-01 |
ARONSON, WILLIAM J (contact); COHEN, PINCHAS |
Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer |
2017 |
R01 |
CA227479-01 |
SIMONE, NICOLE L |
(11) Diet Modification to Augment Radiation for Breast Cancer Brain Metastases |
2019 |
R01 |
CA231239-01A1 |
ACHARYYA, SWARNALI |
Modulating dietary zinc to prevent cachexia and improve survival in cancer |
2019 |
R21 |
CA238953-01 |
VISWANATHAN, SARASWATHI (contact); RACHAGANI, SATYANARAYANA |
Altered Histidine Metabolism in Pancreatic Cancer: A Novel Metabolic Target to Enhance Gemcitabine Efficacy |
2019 |
R21 |
CA242270-01 |
KAISER, PETER |
Methionine Dependency of Cancer |
2017 |
R21 |
CA231255-01 |
ROSENBERG, DANIEL WILLIAM |
(PQ11) Dietary strategies to enhance FOLFOX cancer therapies |
2019 |
R01 |
CA227230-01A1 |
CHEN, SHIUAN (contact); LAU, CLAYTON; TWARDOWSKI, PRZEMYSLAW WIKTOR |
(PQ11) Immune modulatory effects of white button mushroom in prostate cancer - A translational research |
2017 |
R21 |
CA227528-01 |
WEICHSELBAUM, RALPH R |
(PQ10) Understanding How Commensal Microbiota Affect the Anti-tumor Action of Radiotherapy |
2017 |
R01 |
CA219896-01A1 |
WARGO, JENNIFER A |
(PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome |
2017 |
R01 |
CA219871-01A1 |
FACCIABENE, ANDREA (contact); KOUMENIS, CONSTANTINOS |
(PQ10) The impact of the gut microbiome on the anti-tumor effects of radiotherapy |
2019 |
R21 |
CA231273-01A1 |
WEICHSELBAUM, RALPH R |
Microbiota and the anti-tumor action of anti-CD47 immunomodulation. |
2017 |
R21 |
CA227232-01 |
TURNBAUGH, PETER JAMES (contact); ATREYA, CHLOE E |
(PQ10) Harnessing the human gut microbiome to predict chemotherapy outcomes |
2019 |
R01 |
CA231303-01A1 |
KOH, ANDREW Y (contact); HOMSI, JADE ; PASARE, CHANDRASHEKHAR |
Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitory Therapy for Cancer |
2019 |
R01 |
CA242305-01 |
JAMES, LINDSEY INGERMAN |
Discovery of first-in-class nsd2 degraders for cancer therapy |
2019 |
R01 |
CA238570-01 |
CREWS, CRAIG M |
Developing Tumor-specific PROTACs |
2017 |
R01 |
CA230854-01 |
JIN, JIAN (contact); PARSONS, RAMON E |
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer |
2019 |
R01 |
CA242003-01 |
ZHOU, DAOHONG (contact); TREVINO, JOSE G; ZHENG, GUANGRONG |
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer |
2017 |
R01 |
CA231295-01 |
OSMAN, IMAN (contact); WEBER, JEFFREY S |
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition |
2017 |
R01 |
CA227466-01 |
ZIV, ELAD |
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy |
2019 |
R21 |
CA231277-01A1 |
MOR, ADAM |
(PQ8) Predictive biomarkers for the onset of immune-related adverse events associated with PD-1 blockade |
2017 |
R01 |
CA231291-01 |
WELLSTEIN, ANTON (contact); ATKINS, MICHAEL BENJAMIN |
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors |
2019 |
R01 |
CA227481-01A1 |
BALKO, JUSTIN M (contact); JOHNSON, DOUGLAS B |
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition |
2019 |
R21 |
CA231280-01A1 |
FANTL, WENDY JANE (contact); LEPPERT, JOHN THOMAS |
(PQ8) Biomarker identification by mass cytometry in peripheral blood of patients with renal cell carcinoma undergoing immune checkpoint therapy |
2019 |
R01 |
CA231226-01A1 |
BUCKNER, JANE HOYT (contact); CHOW, LAURA ; LINSLEY, PETER S; WAMBRE, ERIC |
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy |
2017 |
R01 |
CA227505-01 |
KIRCHHOFF, TOMAS (contact); WEBER, JEFFREY S |
(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade |
2019 |
R01 |
CA238471-01 |
DHODAPKAR, KAVITA (contact); SANZ, IGNACIO E |
B cells in autoimmunity following checkpoint blockade therapy |
2019 |
R01 |
CA238998-01 |
WEIDHAAS, JOANNE B |
Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibition |
2017 |
R01 |
CA227473-01 |
HEROLD, KEVAN C (contact); KLUGER, HARRIET M |
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors |
2017 |
R21 |
CA231252-01A1 |
ASTSATUROV, IGOR (contact); CUKIERMAN, EDNA |
Oncogenic Synapses: cell-cell contacts enabling trogocytic-based metabolic interactions between pancreatic cancer and fibroblastic stromal cells |
2019 |
R01 |
CA242226-01 |
ROGERS, GREGORY CHARLES (contact); CRESS, ANNE E |
Centrosome instability as a mechanism to promote localized prostate cancer |
2019 |
R21 |
CA231269-01A1 |
LUSK, CHARLES PATRICK (contact); KING, MEGAN C |
Leveraging cancer-specific defects in nuclear integrity to inform novel synthetic lethal strategies |
2019 |
R01 |
CA231300-01A1 |
BIVONA, TREVER G (contact); HUANG, BO |
(PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules |
2017 |
R21 |
CA227381-01 |
GADDAMEEDHI, SHOBHAN |
Chronotherapy as a Strategy to Attenuate Toxicity Associated with Cisplatin and Radiation Treatment for Triple-Negative Breast Cancer |
2017 |
R01 |
CA230848-01 |
FU, LONING NONE (contact); MOORE, DAVID D |
(PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis |
2017 |
R21 |
CA227379-01 |
HONG, CHRISTIAN I |
(PQ6) Roles of circadian rhythms in tumor development |
2019 |
R01 |
CA231321-01A1 |
BURCH, JAMES |
Role of Circadian Factors in Inflammation and Colorectal Adenoma Risk |
2017 |
R21 |
CA227375-01 |
REPASKY, ELIZABETH A (contact); ANTOCH, MARINA |
(PQ6): Is Adrenergic Stress-induced Immune Suppression at the Crossroads of Circadian Rhythm Disruption and Cancer? |
2019 |
R01 |
CA231122-01A1 |
HELLER, H CRAIG |
(#6) A novel animal model for determining the role of circadian timing in breast cancer development |
2019 |
R01 |
CA238988-01 |
FU, LONING NONE (contact); MOORE, DAVID D |
Sympathetic circadian dysfunction in obesity-related hepatocarcinogenesis |